[go: up one dir, main page]

PL3310809T3 - Preparat przeciwciała przeciwko cgrp - Google Patents

Preparat przeciwciała przeciwko cgrp

Info

Publication number
PL3310809T3
PL3310809T3 PL16729483.4T PL16729483T PL3310809T3 PL 3310809 T3 PL3310809 T3 PL 3310809T3 PL 16729483 T PL16729483 T PL 16729483T PL 3310809 T3 PL3310809 T3 PL 3310809T3
Authority
PL
Poland
Prior art keywords
antibody formulation
cgrp antibody
cgrp
formulation
antibody
Prior art date
Application number
PL16729483.4T
Other languages
English (en)
Inventor
Anant N. SHARMA
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3310809T3 publication Critical patent/PL3310809T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16729483.4T 2015-06-17 2016-06-08 Preparat przeciwciała przeciwko cgrp PL3310809T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17
PCT/US2016/036407 WO2016205037A1 (en) 2015-06-17 2016-06-08 Anti-cgrp antibody formulation

Publications (1)

Publication Number Publication Date
PL3310809T3 true PL3310809T3 (pl) 2025-01-27

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16729483.4T PL3310809T3 (pl) 2015-06-17 2016-06-08 Preparat przeciwciała przeciwko cgrp

Country Status (30)

Country Link
US (3) US11498959B2 (pl)
EP (2) EP4470557A3 (pl)
JP (1) JP6438599B2 (pl)
KR (1) KR102000867B1 (pl)
CN (3) CN114948847A (pl)
AR (1) AR104847A1 (pl)
AU (1) AU2016280555B2 (pl)
BR (1) BR112017023374A2 (pl)
CA (1) CA2984185A1 (pl)
DK (1) DK3310809T3 (pl)
EA (1) EA037580B1 (pl)
ES (1) ES3000607T3 (pl)
FI (1) FI3310809T3 (pl)
HK (1) HK1245813A1 (pl)
HR (1) HRP20241660T1 (pl)
HU (1) HUE069368T2 (pl)
IL (2) IL292562A (pl)
JO (1) JO3772B1 (pl)
LT (1) LT3310809T (pl)
MA (1) MA49726B1 (pl)
MX (1) MX2017016199A (pl)
MY (1) MY184266A (pl)
NZ (1) NZ737046A (pl)
PL (1) PL3310809T3 (pl)
PT (1) PT3310809T (pl)
RS (1) RS66243B1 (pl)
TW (1) TWI725973B (pl)
UA (1) UA120881C2 (pl)
WO (1) WO2016205037A1 (pl)
ZA (1) ZA201707324B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ES2974803T3 (es) 2014-03-21 2024-07-01 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina y métodos para utilizarlos
WO2018055573A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
KR20200139720A (ko) * 2018-04-02 2020-12-14 암젠 인크 에레누맙 조성물 및 이의 용도
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-cgrp antibodies
JOP20210247A1 (ar) * 2019-05-02 2023-01-30 H Lundbeck As علاج الصداع باستخدام أجسام مضادة لـ cgrp
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
WO2004071439A2 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0608815B1 (pt) * 2005-03-08 2021-10-13 Pfizer Products Inc Composições de anticorpo anti-ctla-4
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
SI2380592T1 (en) 2005-11-14 2018-06-29 Teva Pharmaceuticals International Gmbh The antibody to the calcitonin-related peptide antagonist
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
PE20081610A1 (es) * 2007-01-09 2008-12-09 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos
JP2010522208A (ja) * 2007-03-22 2010-07-01 イムクローン・リミテッド・ライアビリティ・カンパニー 安定な抗体処方物
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
EP3329911A1 (en) * 2008-09-19 2018-06-06 Pfizer Inc Stable liquid antibody formulation
JP5823867B2 (ja) 2008-10-29 2015-11-25 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の製剤
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20120148576A1 (en) * 2009-03-06 2012-06-14 Medlmmune, Llc Humanized anti-cd 19 antibody formulations
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
EP2608805B1 (en) * 2010-08-23 2017-07-05 Wyeth LLC STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
AR086516A1 (es) * 2011-05-20 2013-12-18 Alderbio Holdings Llc Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso
MX2014004981A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes dirigidos contra tnf.
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
AU2014209994B2 (en) * 2013-01-24 2017-03-16 Glaxosmithkline Intellectual Property Development Limited TNF-alpha antigen-binding proteins
ES2974803T3 (es) * 2014-03-21 2024-07-01 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina y métodos para utilizarlos

Also Published As

Publication number Publication date
EP4470557A2 (en) 2024-12-04
DK3310809T3 (da) 2024-12-02
RS66243B1 (sr) 2024-12-31
TWI725973B (zh) 2021-05-01
HRP20241660T1 (hr) 2025-02-14
UA120881C2 (uk) 2020-02-25
US11498959B2 (en) 2022-11-15
PT3310809T (pt) 2024-12-16
JP6438599B2 (ja) 2018-12-19
TW201711697A (zh) 2017-04-01
IL255443B (en) 2022-06-01
US20230159628A1 (en) 2023-05-25
AU2016280555B2 (en) 2018-11-15
MY184266A (en) 2021-03-30
HUE069368T2 (hu) 2025-02-28
US20180134772A1 (en) 2018-05-17
CN118356393A (zh) 2024-07-19
AR104847A1 (es) 2017-08-16
EA201792359A1 (ru) 2018-05-31
US20220112277A1 (en) 2022-04-14
MX2017016199A (es) 2018-03-01
ZA201707324B (en) 2020-01-29
BR112017023374A2 (pt) 2018-07-24
MA49726A (fr) 2020-06-10
JP2018517727A (ja) 2018-07-05
MA49726B1 (fr) 2025-02-28
CN114948847A (zh) 2022-08-30
IL255443A0 (en) 2017-12-31
CN107787229A (zh) 2018-03-09
EP3310809A1 (en) 2018-04-25
LT3310809T (lt) 2025-01-10
EA037580B1 (ru) 2021-04-16
EP4470557A3 (en) 2025-02-26
WO2016205037A1 (en) 2016-12-22
FI3310809T3 (fi) 2024-12-07
EP3310809B1 (en) 2024-10-16
AU2016280555A1 (en) 2017-11-16
KR102000867B1 (ko) 2019-07-16
CA2984185A1 (en) 2016-12-22
KR20180002858A (ko) 2018-01-08
NZ737046A (en) 2019-09-27
ES3000607T3 (en) 2025-03-03
HK1245813A1 (zh) 2018-08-31
IL292562A (en) 2022-06-01
JO3772B1 (ar) 2021-01-31

Similar Documents

Publication Publication Date Title
HK1245813A1 (zh) 抗-cgrp抗體製劑
HK1254310A1 (zh) 抗garp抗體
IL248802B (en) Antibody formulation
IL256099A (en) antibody
LT3250592T (lt) Antikūnai prieš transtiretiną
ZA201705662B (en) Anti-transthyretin antibodies
IL268889A (en) Anti-EPHA4 antibody
GB201508180D0 (en) Antibodies
GB201515351D0 (en) Antibody
GB201600871D0 (en) Antibody
LT3336185T (lt) Antikūnas
IL257368A (en) antibody
GB201503438D0 (en) Antibodies
GB201513447D0 (en) Antibody
GB201508257D0 (en) Antibody formulations
GB201508437D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201504858D0 (en) Antibodies
GB201502591D0 (en) Antibodies